Plasma Clozapine, Norclozapine, and the Clozapine: Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993-2007

被引:134
|
作者
Couchman, Lewis [1 ]
Morgan, Phillip Edgar [1 ]
Spencer, Edgar Pathrose [2 ]
Flanagan, Robert James [1 ]
机构
[1] Kings Coll Hosp NHS Fdn Trust, Dept Clin Biochem, Toxicol Unit, London, England
[2] St Thomas Hosp, GSTS Pathol, Med Toxicol Lab, London, England
关键词
therapeutic drug monitoring; adherence; smoking habit; clozapine TDM; norclozapine; plasma; clozapine: norclozapine ratio; ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIC-PATIENTS; N-DESMETHYLCLOZAPINE; SMOKING-CESSATION; CLINICAL PHARMACOKINETICS; LIQUID-CHROMATOGRAPHY; SERUM; CONSTIPATION; OLANZAPINE; CIPROFLOXACIN;
D O I
10.1097/FTD.0b013e3181dad1fb
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Therapeutic drug monitoring of plasma clozapine and of its principal plasma metabolite N-desmethylclozapine (norclozapine) (predose or "trough" sample) can help in monitoring adherence, in dose adjustment, and in minimizing the risk of toxicity. To obtain data to assist in the interpretation of analytical results, the results from a clozapine therapeutic drug monitoring service, 1993-2007, have been audited. There were 104,127 samples from 26,796 patients [18,750 (70%) men aged at time of first sample (median, range) 34 (10-89) years, and 7763 (30%) female aged 38 (12-90) years]. Clozapine was not detected (plasma concentration <0.01 mg/L) in 1.5% of samples (prescribed clozapine dose up to 900 mg/d). Plasma clozapine was either below 0.35 mg/L or greater than 0.60 mg/L in 42.5% and 28.4% of samples, respectively; in 0.4% samples plasma clozapine was 2.0 mg/L or more. Although plasma clozapine was broadly related to prescribed dose, there was much variation: 1.2% of samples had plasma clozapine >1.0 mg/L at prescribed clozapine doses up to 150 mg/d (76.2% < 0.35 mg/L), whereas 23.3% of samples had plasma clozapine < 0.35 mg/L at doses of 850 mg/d and over (18.0% > 1.0 mg/L). The highest plasma clozapine and norclozapine concentrations encountered were 4.95 and 2.45 mg/L, respectively. Although the median plasma clozapine: norclozapine ratio was 1.25 at plasma clozapine concentrations < 0.35 mg/L, the median ratio was 2.08 at plasma clozapine concentrations > 1.0 mg/L. Data (median, 10th-90th percentile) for both clozapine and norclozapine by prescribed clozapine dose band are useful in assessing partial adherence. Analysis of the plasma clozapine: norclozapine ratio by clozapine concentration provides clear evidence that clozapine N-demethylation becomes saturated at higher plasma clozapine concentrations and adds urgency to the requirement for dose adjustment should smoking habit change. A clozapine: norclozapine ratio greater then 2 suggests either a nontrough sample, or that clozapine N-demethylation has become saturated.
引用
收藏
页码:438 / 447
页数:10
相关论文
共 16 条
  • [1] PLASMA CLOZAPINE AND NORCLOZAPINE IN RELATION TO PRESCRIBED DOSE AND OTHER FACTORS IN PATIENTS AGED &lt;18 YEARS: DATA FROM A THERAPEUTIC DRUG MONITORING SERVICE, 1994-2010
    Bowskill, S.
    Couchman, L.
    Handley, S.
    Flanagan, R. J.
    Patel, M. X.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (08) : A66 - A66
  • [2] PLASMA CLOZAPINE AND NORCLOZAPINE IN RELATION TO PRESCRIBED DOSE AND OTHER FACTORS IN PATIENTS AGED &lt;18 YEARS: DATA FROM A THERAPEUTIC DRUG MONITORING SERVICE, 1994-2010
    Patel, Maxine X.
    Couchman, Lewis
    Bowskill, Sally V. J.
    Handley, Simon
    Flanagan, Robert J.
    [J]. SCHIZOPHRENIA RESEARCH, 2012, 136 : S114 - S114
  • [3] PLASMA CLOZAPINE AND NORCLOZAPINE IN RELATION TO PRESCRIBED DOSE AND OTHER FACTORS IN PATIENTS AGED 65 YEARS AND OVER: DATA FROM A THERAPEUTIC DRUG MONITORING SERVICE, 1996-2010
    MacCabe, James H.
    Bowskill, Sally
    Couchman, Lewis
    Flanagan, Robert J.
    [J]. SCHIZOPHRENIA RESEARCH, 2012, 136 : S356 - S356
  • [4] Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996-2010
    Bowskill, Sally
    Couchman, Lewis
    MacCabe, James Hunter
    Flanagan, Robert James
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2012, 27 (03) : 277 - 283
  • [5] Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged &lt;18years: data from a therapeutic drug monitoring service, 1994-2010
    Couchman, Lewis
    Bowskill, Sally V. J.
    Handley, Simon
    Patel, Maxine X.
    Flanagan, Robert J.
    [J]. EARLY INTERVENTION IN PSYCHIATRY, 2013, 7 (02) : 122 - 130
  • [6] Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged &lt; 18 years
    Handley, S.
    Couchman, L.
    Bowskill, S.
    Patel, M.
    Flanagan, R.
    [J]. THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 527 - 527
  • [7] Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010
    Bowskill, Sally V. J.
    Patel, Maxine X.
    Handley, Simon A.
    Flanagan, Robert J.
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2012, 27 (05) : 507 - 513
  • [8] A retrospective study of clozapine and norclozapine concentration in patients with schizophrenia: Data from the Therapeutic Drug Monitoring Service, 2019-2022
    Ding, Jing
    Liu, Jianfeng
    Zhang, Yan
    Xing, Huan
    Zhang, Yang
    Li, Luyao
    Zhang, Suo
    Wang, Huiyuan
    Yang, Liu
    Cui, Xiaohua
    [J]. ASIAN JOURNAL OF PSYCHIATRY, 2024, 91
  • [9] SEX DIFFERENCES IN PLASMA CLOZAPINE/NORCLOZAPINE AND OLANZAPINE CONCENTRATIONS IN CLINICAL PRACTICE: DATA FROM A THERAPEUTIC DRUGMONITORING SERVICE
    Couchman, Lewis
    Bowskill, Sally V.
    MacCabe, James H.
    Patel, Maxine X.
    Flanagan, Robert J.
    [J]. SCHIZOPHRENIA RESEARCH, 2012, 136 : S186 - S186
  • [10] A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients
    Schoretsanitis, Georgios
    Kane, John M.
    Ruan, Can-Jun
    Spina, Edoardo
    Hiemke, Christoph
    de Leon, Jose
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (07) : 603 - 621